MedTrace Logo

GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide

NCT03845179 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-03-16

No results posted yet for this study

Summary

This study will investigate if the effect of DPP-4 inhibitors is mediated in part by Glucose-dependent insulinotropic polypeptide.

Conditions

  • Type2 Diabetes

Interventions

OTHER

Placebo

Saline infusion

OTHER

GIP receptor antagonist

Used for infusion on study days

DRUG

DPP-4 inhibitor

Oral administration of DPP-4 inhibitor in active treatment period

OTHER

Placebo tablet

Oral administration of placebo tablet in placebo treatment period

Sponsors & Collaborators

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-29
Primary Completion
2020-02-28
Completion
2020-02-28

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03845179 on ClinicalTrials.gov